Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Pharnext S.A.. (1/3/17). "Press Release: Pharnext Announces the Amendment to the Liquidity Contract with French Broker Gilbert Dupont and the Annual Update on Its Liquidity Agreement". Paris.

Organisations Organisation Pharnext S.A. (Euronext Paris: ALPHA)
  Organisation 2 Société de Bourse Gilbert Dupont
Products Product investment banking
  Product 2 PXT-3003 (Pharnext)
Persons Person Schwich, Pierre (Pharnext 201602– CFO before Cellectis + 3i + Siparex + Next Venture + Corning + Danone + HP)
  Person 2 Coulot, Julie (NewCap 201701)
     


Pharnext SA (FR00111911287 - ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, announced today the amendment to the liquidity contract with French broker Gilbert Dupont and the annual update on its liquidity agreement.


Amendment to the liquidity agreement

On 29 December 2016, an additional cash contribution of €150,000 was made under the liquidity agreement between Pharnext and Société de Bourse Gilbert Dupont.

At the time of the press release announcing the implementation of the liquidity agreement, the liquidity account held the following assets:

? Number of shares: 0
? Cash: €500,000
? Liquidity agreement: annual update

At 31 December 2016, the liquidity account held the following assets:
? Number of shares: 26,925
? Cash: €335,014.25
? At the time the liquidity agreement was set up on 18 July 2016, €500,000 in cash was transferred to the liquidity account, and a further contribution of €150,000 was made on 29 December 2016.


CONTACTS:

Pharnext
Pierre Schwich
Chief Financial Officer
investors@pharnext.com
+33 (0)1 41 09 22 30

Investors Relations (Europe)
NewCap
Julie Coulot
pharnext@newcap.eu
+33 (0)1 44 71 20 40

Investors Relations (U.S.)
Stern Investor Relations, Inc.
Sarah McCabe
sarah@sternir.com
+1 212-362-1200

Media Relations (Europe)
Alize RP
Caroline Carmagnol
Margaux Pronost
pharnext@alizerp.com
+33 (0)1 44 54 36 64

Media Relations (U.S.)
Russo Partners
Tony Russo, Ph.D.
Matt Middleman, M.D.
tony.russo@russopartnersllc.com
matt.middleman@russopartnersllc.com
+1 212-845-4251
+1 212-845-4272


About Pharnext

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY©. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG© might offer several key advantages: efficacy, safety, and robust intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com

PLEODRUG© and PLEOTHERAPY© are registered trademarks by Pharnext

   
Record changed: 2023-06-05

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Pharnext S.A. (Euronext Paris: ALPHA)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News Bayer Aignostics Collaboration 650x300px




» top